Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Century Therapeutics (IPSC) EBITDA Margin (2022 - 2025)

Century Therapeutics (IPSC) has disclosed EBITDA Margin for 4 consecutive years, with 70.12% as the latest value for Q1 2025.

  • Quarterly EBITDA Margin rose 339304.0% to 70.12% in Q1 2025 from the year-ago period, while the trailing twelve-month figure was 9.04% through Dec 2025, up 190829.0% year-over-year, with the annual reading at 9.05% for FY2025, 190854.0% up from the prior year.
  • EBITDA Margin for Q1 2025 was 70.12% at Century Therapeutics, up from 874.84% in the prior quarter.
  • The five-year high for EBITDA Margin was 70.12% in Q1 2025, with the low at 33558.59% in Q2 2023.
  • Average EBITDA Margin over 4 years is 7454.87%, with a median of 3733.93% recorded in 2022.
  • The sharpest move saw EBITDA Margin plummeted -3128208bps in 2023, then surged 2950217bps in 2024.
  • Over 4 years, EBITDA Margin stood at 5861.8% in 2022, then plummeted by -142bps to 14173.13% in 2023, then skyrocketed by 94bps to 874.84% in 2024, then surged by 108bps to 70.12% in 2025.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 70.12%, 874.84%, and 3812.77% for Q1 2025, Q4 2024, and Q3 2024 respectively.